Genetic Information
Gene & Transcript Details
| ID | Status | Details |
|---|---|---|
| NM_000267.1 | Alternative | 8959 nt | 212–8668 |
| NM_000267.3 | Alternative | 12381 nt | 384–8840 |
| NM_000267.2 | Alternative | 12331 nt | 334–8790 |
Variant Details
Clinical & Population Data
Population Frequency
gnomADClinVar
OpenVariant summary: The NF1 c.369C>G (p.Thr123Thr) variant involves the alteration of a non-conserved nucleotide, resulting in a synonymous change. One in silico tool predicts a damaging outcome for this variant. 4/5 splice prediction tools predict no significant impact on normal splicing. However, these predictions have yet to be confirmed by functional studies. This variant was found in 107/121302 control chromosomes (2 homozygotes), predominantly observed in the East Asian subpopulation at a frequency of 0.012034 (104/8642). This frequency is about 58 times the estimated maximal expected allele frequency of a pathogenic NF1 variant (0.0002084), suggesting this is likely a benign polymorphism found primarily in the populations of East Asian origin. The variant was reported in patients in the literature who also carry truncating NF1 mutations, further supporting the benign nature of the variant of interest. In addition, multiple clinical diagnostic laboratories/reputable databases classified this variant as likely benign/benign. Taken together, this variant is classified as benign.
"This variant has been reported in ClinVar as Benign (13 clinical laboratories) and as Likely benign (4 clinical laboratories)."
COSMIC Somatic Evidence
Open
Functional Impact & Domains
Functional Domain
Error in OpenAI Consolidation. OncoKB: NF1T123=NF1T123=SomaticNCBI Gene:4763|Show additional gene information Variant OverviewNF1, a negative regulator of RAS, is inactivated by mutation or deletion in various solid and hematologic malignancies.This is a synonymous mutation and is not annotated by OncoKB. JAX-CKB: No results found
Click on previews to view full database entries. External databases may require institutional access.
Computational Analysis
Pathogenicity Predictions
SpliceAISpliceAI Scores
Window: ±500bp| Effect Type | Score | Position |
|---|---|---|
| Acceptor Loss (AL) | 0.0 | -32 bp |
| Donor Loss (DL) | 0.0 | 114 bp |
| Acceptor Gain (AG) | 0.0 | 11 bp |
| Donor Gain (DG) | 0.0 | -329 bp |
VCEP Guidelines
Applied ACMG/AMP Criteria (VCEP Specific)
PM2 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
BP4 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)
BP6 (Unknown (Pre-LLM))
From pre-LLM assessment (LLM Failed)